Light-chain Amyloidosis
📧 Sign up to get email alerts when something new happens for Light-chain Amyloidosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis [Phase 2]
A Phase II clinical trial is evaluating teclistamab in previously treated light-chain (AL) amyloidosis and is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. [Phase 1, Phase 2]
Phase 1b/2 study of a dual-target CD19/BCMA CAR T cell therapy for relapsed or refractory light-chain (AL) amyloidosis is currently recruiti…
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis [Phase 3]
A Phase 3 study evaluating birtamimab in Mayo Stage IV AL amyloidosis was terminated, but results have been posted on 2025-12-16.
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis [Phase 2]
This entry reports a Phase 2 clinical trial evaluating the efficacy and safety of CM336 Injection for primary light-chain amyloidosis, curre…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis [NA]
A clinical trial investigating minimal residual disease in patients with systemic light-chain (AL) amyloidosis, sponsored by Peking Universi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating SAR445514 in relapsed/refractory multiple myeloma and light-chain amyloidosis has been terminated.
-
CLINICAL_TRIALS research · 2025-06-03Clinical Trial Update: Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) [Phase 2]
Phase 2 clinical trial evaluating a combination of daratumumab, venetoclax, and dexamethasone for newly diagnosed light-chain amyloidosis wi…
-
CLINICAL_TRIALS trial_result · 2025-05-25Clinical Trial Update: Teclistamab in Previously Treated AL Amyloidosis [Phase 2]
A Phase 2 clinical trial evaluating teclistamab for previously treated light-chain (AL) amyloidosis is currently recruiting.
-
CLINICAL_TRIALS research · 2025-05-21Clinical Trial Update: Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis [NA]
An exploratory clinical study is evaluating the safety and potential efficacy of BCMA-targeted autologous CAR T cell injections in patients …
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis [Phase 2]
This phase 2 study is evaluating the CAR-T therapy HBI0101 (NXC-201) in patients with multiple myeloma (refractory or relapsed) and light-ch…
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis [Phase 2]
A Phase 2 trial update reporting completion of daratumumab monotherapy in previously untreated patients with Stage 3B light chain (AL) amylo…
-
CLINICAL_TRIALS research · 2025-01-22Clinical Trial Update: Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14) [Phase 2]
Phase 2 trial of venetoclax plus dexamethasone for newly diagnosed light-chain (AL) amyloidosis with t(11;14) translocation; currently activ…
-
CLINICAL_TRIALS trial_result · 2025-01-09Clinical Trial Update: DapagliFLOzin in Renal AL Amyloidosis (FLORAL) [Phase 2]
A Phase 2 trial called FLORAL is evaluating the SGLT2 inhibitor dapagliflozin in light-chain (AL) amyloidosis with renal involvement. The st…
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: Screening to Improve Survival in AL Amyloidosis
The clinical trial update reports completion of a screening-based study aimed at improving survival in light-chain (AL) amyloidosis. The stu…
-
CLINICAL_TRIALS withdrawal · 2024-10-18Clinical Trial Update: Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis [Phase 2]
A Phase 2 trial evaluating isatuximab with bendamustine for systemic light-chain (AL) amyloidosis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2024-07-08Clinical Trial Update: A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice
This completed clinical trial studied how the duration of treatment relates to patient response in real-world cases of multiple myeloma or l…
-
CLINICAL_TRIALS trial_result · 2023-01-17Clinical Trial Update: Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis [Phase 1, Phase 2]
A clinical trial update for STI-6129 in relapsed or refractory systemic AL amyloidosis (Phase 1/Phase 2) with unknown status.
-
CLINICAL_TRIALS trial_result · 2018-08-28Clinical Trial Update: Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis [Phase 1, Phase 2]
Phase 1/2 open-label dose-escalation trial of NEOD001 in subjects with light chain (AL) amyloidosis completed.
-
CLINICAL_TRIALS withdrawal · 2018-03-21Clinical Trial Update: High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease [Phase 2]
A Phase 2 clinical trial evaluating high-cutoff hemodialysis in patients with advanced cardiac AL amyloidosis and end-stage renal disease ha…
-
CLINICAL_TRIALS trial_result · 2017-10-17Clinical Trial Update: A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) [Phase 2]
This update notes the completion of a Phase 2 trial evaluating epigallocatechin-3-gallate (EGCG) for cardiac involvement in light chain (AL)…
-
FDA approval · 2017-06-16FDA Approved: DARZALEX — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for DARZALEX (daratumumab) submitted by Janssen Biotech, Inc. to modify/expand the approved use.
-
CLINICAL_TRIALS trial_result · 2011-05-10Clinical Trial Update: Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis [Phase 1, Phase 2]
This clinical trial update reports the completion of a Phase 1/2 study evaluating lenalidomide in combination with melphalan and dexamethaso…
-
CLINICAL_TRIALS trial_result · 2010-08-13Clinical Trial Update: Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis [Phase 1, Phase 2]
Open-label Phase 1/2 study of VELCADE (bortezomib) for injection in patients with light-chain (AL) amyloidosis has completed, with results p…